4th Gen EGFR Inhibitor
We are always open to new potential opportunities to establish strategic collaborations.
Genosco’s pipelines consist of 2 assets in Phase II/III, 1 asset in Phase I and multiple preclinical programs.
Genosco is a clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.
Partnering with Genosco
We are always open to new potential opportunities to establish strategic collaborations to develop our product candidates.